Loading…
Loading…
LFMD does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for LFMD and 80,000+ other tickers.
See exactly how LFMD's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LFMD and 80,000+ other tickers.
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical…
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, announces that it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on November 9, 2026, and will host a conference call beginning at 8:30 a.m. Eastern time.
LifeMD (NASDAQ: LFMD - Get Free Report) and GeneDx (NASDAQ: WGS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Profitability This table compares LifeMD and GeneDx's net margins,
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.
LifeMD remains a Buy despite disappointing Q2 2026 results, with revenue and EBITDA guidance revised downward and a sequential subscriber decline. LFMD's core business model is profitable at an 88% gross margin, but elevated customer acquisition costs—now 59% of revenue—are pressuring EBITDA. Management is shifting strategy from auction-based marketing to partnerships with manufacturers, employers, and insurers, aiming to reduce CAC and leverage branded GLP-1 therapies.